PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D change of 44.99% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-4.08%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses change of 80.19% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
21.99%
Operating expenses change of 21.99% versus flat Biotechnology costs. Walter Schloss would verify control.
21.99%
Total costs change of 21.99% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A change of 80.19% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
32.89%
EBITDA change of 32.89% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses change of 198.65% versus flat Biotechnology. Walter Schloss would verify control.
32.68%
Income change of 32.68% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Income change of 32.68% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS change of 32.51% versus flat Biotechnology. Walter Schloss would verify quality.
32.51%
Diluted EPS change of 32.51% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.